StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Research analysts at StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE BTX opened at $6.54 on Friday. The firm has a 50 day moving average price of $3.25 and a two-hundred day moving average price of $1.69. The stock has a market cap of $384.72 million, a P/E ratio of -2.88 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $6.35 and a 52-week high of $8.31.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.